Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России»

В середине 2021 года инфекция SARS-CoV-2 (Severe Acute Respiratory coronavirus 2), вызвавшая пандемию коронавирусной болезни 2019 (coronavirus disease, COVID-19), поразила более 157 млн человек во всех регионах земного шара и привела более чем к 3,2 млн летальных исходов. Предполагается, что у пациентов с иммуновоспалительными ревматическими заболеваниями (ИВРЗ) пожилой возраст, неконтролируемое воспаление, противовоспалительная терапии, коморбидная патология, генетические и другие факторы потенциально могут приводить к увеличению восприимчивости к вирусным и бактериальным инфекциям, в том числе к SARS-CoV-2. В новой версии рекомендаций Общероссийской общественной организации «Ассоциация ревматологов России» сформулированы основные положения, касающиеся тактики ведения пациентов с ИВРЗ в период продолжающейся пандемии COVID-19.

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9

2. World Health Organization. Coronavirus Disease (COVID-2019). Situation Reports (World Health Organization, 2020).

3. Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-132. doi: 10.14412/1995-4484-2020-123-132

4. Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Научно-практическая ревматология. 2021;59(1):5-30. doi: 10.47360/1995-4484-2021-5-30

5. Насонов ЕЛ, Бекетова ТВ, Решетняк ТМ, Лила АМ, Ананьева ЛП, Лисицына ТА, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета. Научно-практическая ревматология. 2020;58(4):353-367. doi: 10.47360/1995-4484-2020-353-367

6. Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi: 10.47360/1995-4484-2021-119-128

7. Белов БС, Лила АМ. COVID-19 и ревматология: год спустя. Научно-практическая ревматология. 2021;59(1):31-36. doi: 10.47360/1995-4484-2021-31-36

8. Насонов ЕЛ. Иммунопатология и иммунофармакотерапия коронавирусной болезни 2019 (COVID-19): фокус на интерлейкин 6. Научно-практическая ревматология. 2020;58(3):245-261. doi: 10.14412/1995-4484-2020-245-261

9. Насонов ЕЛ. Коронавирусная болезнь 2019 (COVID-19): вклад ревматологии. Терапевтический архив. 2021;93(5):537-550. doi: 10.2644/00403660.2021.05.200799

10. Merrill J, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16(10):581-589. doi: 10.1038/s41584-020-0474-5

11. Schett G, Manger B, Simon D, Caporali R. COVID-19 revisiting inflammatory pathways of arthritis. Nat Rev Rheumatol. 2020;16(8):465-470. doi: 10.1038/s41584-020-0451-z

12. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-162. doi: 10.1097/BOR.0000000000000776

13. Nissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, et al. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol. 2021;3(6):e447-e459. doi: 10.1016/S2665-9913(21)00062-X

14. Angriman F, Ferreyro BL, Burry L, Fan E, Ferguson ND, Husain S, et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med. 2021;9(6):655-664. doi: 10.1016/S2213-2600(21)00139-9

15. Alunno A, Najm A, Mariette X, De Marco G, Emmel J, Mason L, et al. Immunomodulatory therapies for SARS-CoV-2 infection: A systematic literature review to inform EULAR points to consider. Ann Rheum Dis. 2021;80(6):803-815. doi: 10.1136/annrheumdis-2020-219725

16. Ramos-Casals M, Brito-Zerón P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol. 2021;17(6):315-332. doi: 10.1038/s41584-021-00608-z.

17. Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol.2020; 16(8):413-414. doi: 10.1038/s41584-020-0448-7.

18. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020;19:141-154. doi: 10.1038/s41579-020-00459-7

19. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451-2460. doi: 10.1056/NEJMcp2009575

20. Zhou T, Su TT, Mudianto T, Wang J. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. J Exp Med. 2020;217(10):e20200674. doi: 10.1084/jem.20200674

21. Machado PM. Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. RMD Open. 2021;7(1):e001549. doi: 10.1136/rmdopen-2020-001549

22. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255-2273. doi: 10.1056/NEJMra2026131.

23. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5

24. Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory syndromes associated with SARS-CoV-2 infection: Dysregulation of the immune response across the age spectrum. J Clin Invest. 2020;130(12):6194-6197. doi: 10.1172/JCI145301

25. Kingsmore KM, Grammer AC, Lipsky PE. Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases. Nat Rev Rheumatol. 2020;16(1):32-52. doi: 10.1038/s41584-019-0337-0

26. Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):e428-e436. doi: 10.1016/S2665-9913(20)30120-X

27. Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020;111:102468. doi: 10.1016/j.jaut.2020.102468

28. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. doi: 10.1016/j.autrev.2020.102567

29. Novelli L, Motta F, De Santis M, Ansari AA, Gershwin ME, Selmi C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 – A systematic review of the literature. J Autoimmunity. 2021;117:102592. doi: 10.1016/j.jaut.2020.102592

30. Ciaffi J, Meliconi R, Ruscitti P, Berardicurti O, Giacomelli R, Ursini F. Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC Rheumatol. 2020;4:65. doi: 10.1186/s41927-020-00165-0

31. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3

32. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. medRxiv.2021.01.27.21250617. doi: 10.1101/2021.01.27.21250617

33. Gasparotto M, Framba V, Piovella C, Doria A, Iaccarino L. PostCOVID-19 arthritis: A case report and literature review. Clin Rheumatol. 2021 Feb 15:1-6. doi: 10.1007/s10067-020-05550-1

34. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615. doi: 10.1038/s41591-021-01283-z

35. Ferri C, Giuggioli D, Raimondo V, L’Andolina M, Tavoni A, Cecchetti R, et al. COVID-19 and rheumatic autoimmune systemic diseases: Report of a large Italian patients series. Clin Rheumatol. 2020;39(11):3195-3204. doi: 10.1007/s10067-020-05334-7

36. Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, et al. COVID19 in patients with rheumatic disease in Hubei province, China: A multicentre retrospective observational study. Lancet Rheumatol. 2020;2(9):e557-e564. doi: 10.1016/S2665-9913(20)30227-7

37. Favalli EG, Monti S, Ingegnoli F, Balduzzi S, Caporali R, Montecucco C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol (Hoboken, NJ). 2020;72(10):1600-1606. doi: 10.1002/art.41388

38. Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50(4):564-570. doi: 10.1016/j.semarthrit.2020.05.001

39. Aries P, Iking-Konert C. No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany). Ann Rheum Dis. 2020 Aug 7. doi: 10.1136/annrheumdis-2020-218400

40. Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Jt Bone Spine. 2020;87(5):439-443. doi: 10.1016/j.jbspin.2020.05.003

41. Zen M, Fuzzi E, Astorri D, Saccon F, Padoan R, Ienna L, et al. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients. J Autoimmun. 2020;112:102502. doi: 10.1016/j.jaut.2020.102502

42. Blanch-Rubió J, Soldevila-Domenech N, Tío L, LlorenteOnaindia J, Ciria-Recasens M, Polino L, et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging. 2020;12(20):19923-19937. doi: 10.18632/aging.104117

43. Pablos JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, Blanco R, Castrejón I, et al. Prevalence of hospital PCR-confirmed COVID19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis. 2020;79(9):1170-1173. doi: 10.1136/annrheumdis-2020-217763

44. Benucci M, Damiani A, Giannasi G, Li Gobbi F, Quartuccio L, Grossi V, et al. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD. Ann Rheum Dis. 2020 Jul 6. doi: 10.1136/annrheumdis-2020-218214

45. So H, Mak JW, So J, Lui G, Lun F, Lee J, et al. Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study. Semin Arthritis Rheum. 2020;50(5):885-889. doi: 10.1016/j.semarthrit.2020.07.012

46. Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020;33(5):e13475. doi: 10.1111/dth.13475

47. Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, et al. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: A population-based study. Ann Rheum Dis. 2020;79(7):986-988. doi: 10.1136/annrheumdis-2020-217903

48. Mena Vázquez N, Manrique-Arija S, Cabezudo-García P, GodoyNavarrete FJ, Cabezas-Lucena AM, Morales-Águila M, et al. Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases. Int J Clin Pract. 2020 Sep 15. doi: 10.1111/ijcp.13707

49. Jovani V, Calabuig I, Peral-Garrido ML, Tovar-Sugrañes E, López-González MD, Bernabeu P, et al. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Ann Rheum Dis. 2020 Jun 25. doi: 10.1136/annrheumdis-2020-218152

50. Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study. Ann Rheum Dis. 2020;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296

51. D’Silva KM, Serling-Boyd N, Wallwork R, Hsu T, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020;79(9):1156-1162. doi: 10.1136/annrheumdis-2020-217888

52. Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F. COVID-19 in patients with rheumatic diseases in northern Italy: A single-centre observational and case-control study. Lancet Rheumatol. 2020;2(9):e549-e556. doi: 10.1016/S2665-9913(20)30169-7

53. Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593-1598. doi: 10.1007/s00296-020-04676-4

54. Freites Nuñez DD, Leon L, Mucientes A, RodriguezRodriguez L, Font Urgelles J, Madrid García A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(11):1393-1399. doi: 10.1136/annrheumdis-2020-217984

55. Nuño L, Novella Navarro M, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis. 2020;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054

56. Fernandez-Ruiz R, Masson M, Kim MY, Myers B, Haberman RH, Castillo R, et al. Leveraging the United States epicenter to provide insights on COVID-19 in patients with systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ). 2020;72(12):1971-1980. doi: 10.1002/art.41450

57. Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol (Hoboken, NJ). 2020;72(12):1981-1989. doi: 10.1002/art.41456

58. Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, et al. COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol. 2020;38(4):748-753.

59. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871

60. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance; COVID-19 Global Rheumatology Alliance Consortium. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 Jan 27. doi: 10.1136/annrheumdis-2020-219498

61. Saadoun D, Vieira M, Vautier M, Baraliakos X, Andreica I, da Silva JAP, et al. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: The Euro-COVIMID multicentre crosssectional study. Lancet Rheumatol. 2021 Apr 28. doi: 10.1016/S2665-9913(21)00112-0

62. Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.; COVID-19 Global Rheumatology Alliance. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 May 28. doi: 10.1136/annrheumdis-2021-220418

63. England BR, Roul P, Yang Y, Kalil AC, Michaud K, Thiele GM, et al. Risk of COVID-19 in rheumatoid arthritis: A National Veterans affairs matched cochort study in at-risk individuals. Arthritis Rheum. 2021 May 5. doi: 10.1002/art.41800

64. D’Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, et al. COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: A US multicenter, comparative cohort study. Arthritis Rheumatol. 2021;73(6):914-920. doi: 10.1002/art.41619

65. Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, et al. High levels of immunosuppression are related to unfavorable outcome in hospitalized patients with rheumatic disease and COVID-19: First results of ReumaCoV Brasil Registry. RMD Open. 2021;7e0011461. doi: 10.1136/tmodopen-2020-001461

66. Cordtz R, Lindhardsen J, Soussi BG, Vela J, Uhrenholt L, Westermann R, et al. Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark. Rheumatology (Oxford). 2020 Dec 28:keaa897. doi: 10.1093/rheumatology/keaa897

67. Attauabi M, Seidelin JB, Felding OK, Wewer MD, Vinther Arp LK, Sarikaya MZ, et al. Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study. J Autoimmun. 2021;118:102613. doi: 10.1016/j.jaut.2021.102613

68. Peach E, Rutter M, Lanyon P, Grainge MJ, Hubbard R, Aston J, et al. Risk of death among people with rare autoimmune diseases compared to the general population in England during the 2020 COVID-19 pandemic. Rheumatology. 2020;60(4):1902-1909. doi: 10.1093/rheumatology/keaa855

69. Hsu TY, D’Silva KM, Patel NJ, Wang J, Mueller AA, Fu X, et al. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: A retrospective, comparative cohort study. Lancet Rheumatol. 2021 May 28. doi: 10.1016/S2665-9913(21)00140-5

70. FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2020;80(4):527-538. doi: 10.1136/annrheumdis-2020-218310

71. Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, et al. COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021 Mar 16. doi: 10.1093/rheumatology/keab250

72. Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi: 10.1136/rmdopen-2020-001464

73. Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020 Oct 13. doi: 10.1136/annrheumdis-2020-218946

74. Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: A systematic review and meta-analysis. Rheumatol Int. 2021;41(5):851-861. doi: 10.1007/s00296-021-04803-9

75. Yang H, Xu J, Shi L, Duan G, Wang Y. Correspondence on «Prevalence and clinical outocome of COVIF-19 in patients with autoimmune diseases: A systemic reviews and meta-analysis. Ann Rheum Dis. 2021;0:1-3. doi: 10.1136/annrheumdis-2020-219821

76. Baillet A, Gossec L, Carmona L, Wit Md, van Eijk-Hustings Y, Bertheussen H, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative. Ann Rheum Dis. 2016;75(6):965-973. doi: 10.1136/annrheumdis-2016-209233

77. Гордеев АВ, Галушко ЕА, Насонов ЕЛ. Концепция мультиморбидности в ревматологической практике. Научнопрактическая ревматология. 2014;52(4):362-365. doi: 10.14412/1995-4484-2014-362-365

78. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4

79. Bilal J, Berlinberg A, Riaz IB, Faridi W, Bhattacharjee S, Ortega G, et al. Risk of infections and cancer in patients with rheumatologic diseases receiving interleukin inhibitors: A systematic review and meta-analysis. JAMA Netw Open. 2019;2(10):e1913102. doi: 10.1001/jamanetworkopen.2019.13102

80. Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: A viewpoint in 2020. Ann Rheum Dis. 2020;79(12):1532-1543. doi: 10.1136/annrheumdis-2020-217092

81. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53-61. doi: 10.1093/rheumatology/kes305

82. Calabrese LH, Calabrese C, Lenfant T, Kirchner E, Strand V. Infections in the era of targeted therapies: Mapping the road ahead. Front Med (Lausanne). 2020;7:336. doi: 10.3389/fmed.2020.00336

83. Hyrich KL, Machado PM. Rheumatic disease and COVID-19: Epidemiology and outcomes. Nat Rev Rheumatol. 2021;17(2):71-72. doi: 10.1038/s41584-020-00562-2

84. Jethwa H, Sullivan A, Abraham S. COVID-19 and immunomodulatory therapy – Can we use data from previous viral pandemics? J Rheumatol. 2020;47(12):1734-1737. doi: 10.3899/jrheum.200527

85. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V, Furst DE; CORRONA Investigators. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(5):785-791. doi: 10.1136/ard.2010.128637

86. Grainger R, Machado PM, Robinson PC. Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. Best Pract Res Clin Rheumatol. 2021;35(1):101657. doi: 10.1016/j.berh.2020.101657

87. Isaacs JD, Burmester GR. Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. Ann Rheum Dis. 2020;79(8):991-993. doi: 10.1136/annrheumdis-2020-218019

88. Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др., по поручению президиума Общероссийской общественной организации «Ассоциация ревматологов России». Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные (аутоиммунные) ревматические заболевания. Проект рекомендаций Общероссийской общественной организации «Ассоциация ревматологов России». URL: http: //rheumatology.ru (Дата доступа: ##.##.2021).

89. Авдеев СН, Адамян ЛВ, Алексеева УИ, Багненко СФ, Баранов АА, Баранова НН, и др. Профилактика, диагностики и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. М.;2021.

90. Landewé RB, Machado PM, Kroon F, Bijlsma HW, Burmester GR, Carmona L, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851-858. doi: 10.1136/annrheumdis-2020-217877

91. Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 3. Arthritis Rheumatol. 2021;73(2):e1-e12. doi: 10.1002/art.41596

92. Schulze-Koops H, Krüger K, Hoyer BF, Leipe J, Iking-Konert C, Specker C; Commission for Pharmacotherapy and the Board of Directors of the German Society for Rheumatology. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2 – Methodology, key messages and justifying information. Rheumatology (Oxford). 2021 Jan 27. doi: 10.1093/rheumatology/keab072

93. Richez C, Flipo RM, Berenbaum F, Cantagrel A, Claudepierre P, Debiais F, et al. Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. Joint Bone Spine. 2020;87(5):431-437. doi: 10.1016/j.jbspin.2020.05.006

94. Tam LS, Tanaka Y, Handa R, Chang CC, Cheng YK, Isalm N, et al. Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. Int J Rheum Dis. 2020;23(6):717-722. doi: 10.1111/1756-185X.13863

95. Seo MR, Kim JW, Park EJ, Jung SM, Sung YK, Kim H, et al. Korean College of Rheumatology working group. Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic. Korean J Intern Med. 2020;35(6):1317-1332. doi: 10.3904/kjim.2020.417

96. Saldarriaga Rivera LM, Fernández Ávila D, Bautista Molano W, Jaramillo Arroyave D, Bautista Ramírez AJ, et al. Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology. Reumatol Clin (Engl Ed). 2020;16(6):437-446. doi: 10.1016/j.reuma.2020.06.011

97. Akintayo RO, Bahiri R, El Miedany Y, Olaosebikan H, Kalla AA, Adebajo AO, et al. African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic. Clin Rheumatol. 2020 Sep 2:1-10. doi: 10.1007/s10067-020-05355-2

98. Price E, MacPhie E, Kay L, Lanyon P, Griffiths B, Holroyd C, et al. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med (Lond). 2020;20(3):256-261. doi: 10.7861/clinmed.2020-0160

99. Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, et al. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. J Eur Acad Dermatol Venereol. 2021 Feb 3. doi: 10.1111/jdv.17075

100. Barlow-Pay F, Htut TW, Khezrian M, Myint PK. Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Drug Saf. 2021;12:2042098620985687. doi: 10.1177/2042098620985687

101. Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 1. Arthritis Rheumatol. 2021 Mar 17. doi: 10.1002/art.41734

102. Hazlewood GS, Pardo J, Barnabe C, Schieir O, Barber CEH, Bernatsky S, et al. Canadian Rheumatology Association recommendation for the use of COVID-19 vaccination for patients with autoimmune rheumatic diseases. J Rheumatol. 2021 May 15. doi: 10.3899/jrheum.210288

103. Santosa A, Xu C, Arkachaisri T, Kong KO, Lateef A, Lee TH, et al. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists. Int J Rheum Dis. 2021 May 10. doi: 10.1111/1756-185X.14107

104. Park JK, Lee EB, Shin K, Sung YK, Kim TH, Kwon SR, et al. Korean College of Rheumatology task force for COVID-19 vaccine guidance for patients with autoimmune inflammatory rheumatic diseases. COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: Clinical guidance of the Korean College of Rheumatology. J Korean Med Sci. 2021;36(12):e95. doi: 10.3346/jkms.2021.36.e95

105. Arnold J, Winthrop K, Emery P. COVID-19 vaccination and antirheumatic therapy. Rheumatology (Oxford). 2021 Mar 12. doi: 10.1093/rheumatology/keab223

106. Soy M, Keser G, Atagunduz P, Mutlu MY, Gunduz A, Koybaşi G, Bes C. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review. Clin Rheumatol. 2021 Mar 22:1-13. doi: 10.1007/s10067-021-05700-z

107. Furer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, et al. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open. 2021;7(1):e001594. doi: 10.1136/rmdopen-2021-001594

108. Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P, et al. How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: An expert opinion by IMIDs Study Group. Front Immunol. 2021;12:656362. doi: 10.3389/fimmu.2021.656362

109. Hooijberg F, Boekel L, Vogelzang EH, Leeuw M, Boers M, van Vollenhoven R, et al. Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. Lancet Rheumatol. 2020;2(10):e583-e585. doi: 10.1016/S2665-9913(20)30286-1

110. Avouac J, Drumez E, Hachulla E, Seror R, Georgin-Lavialle S, El Mahou S, et al.; FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors; FAIR/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol. 2021;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X

111. Bower H, Frisell T, Di Giuseppe D, Delcoigne B, Ahlenius GM, Baecklund E, et al.; ARTIS Study Group. Impact of the COVID19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis. 2021 Feb 23. doi: 10.1136/annrheumdis-2021-219845

112. Kow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int. 2020;40:2117-2118. doi: 10.1007/s00296-020-04715-0

113. Loarce-Martos J, García-Fernández A, López-Gutiérrez F, GarcíaGarcía V, Calvo-Sanz L, Del Bosque-Granero I, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015-2021. doi: 10.1007/s00296-020-04699-x

114. Aviv R, Weber A, Anzum T, Federbush M, Horowitz D, Singas E. Prolonged COVID-19 disease in a patient with rheumatoid arthritis on rituximab therapy. J Infect Dis. 2021 May 8. doi: 10.1093/infdis/jiab248

115. Jones JM, Faruqi AJ, Sullivan JK, Calabrese C, Calabrese LH. COVID-19 outcomes in patients undergoing B cell depletion therapy and those with humoral immunodeficiency states: A scoping review. Pathog Immun. 2021;6(1):76-103. doi: 10.20411/pai.v6i1.435

116. Mehta B, Pedro S, Ozen G, Kalil A, Wolfe F, Mikuls T, et al. Serious infection risk in rheumatoid arthritis compared with noninflammatory rheumatic and musculoskeletal diseases: A US national cohort study. RMD Open. 2019;5(1):e000935. doi: 10.1136/rmdopen-2019-000935

117. Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis. Lancet. 2015;386(9990):258-265. doi: 10.1016/S0140-6736(14)61704-9

118. George MD, Baker JF, Winthrop K, Hsu JY, Wu Q, Chen L, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: A cohort study. Ann Intern Med. 2020;173(11):870-878. doi: 10.7326/M20-1594

119. Каратеев АЕ, Насонов ЕЛ, Лила АМ. Вызывают ли нестероидные противовоспалительные препараты специфические осложнения при коронавирусной инфекции COVID-19? Научно-практическая ревматология. 2020;58(3):340-343. doi: 10.14412/1995-4484-2020-340-343

120. Kelleni MT. Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes. Biomed Pharmacother. 2021;133:110982. doi: 10.1016/j.biopha.2020.110982

121. Baghaki S, Yalcin CE, Baghaki HS, Aydin SY, Daghan B, Yavuz E. COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies. Int J Infect Dis. 2020;101:29-32. doi: 10.1016/j.ijid.2020.09.1466

122. Drake TM, Fairfield CJ, Pius R, Knight SR, Norman L, Girvan M, et al.; ISARIC4C Investigators. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: A matched, prospective cohort study. Lancet Rheumatol. 2021 May 7. doi: 10.1016/S2665-9913(21)00104-1

123. Lund LC, Kristensen KB, Reilev M, Christensen S, Thomsen RW, Christiansen CF, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study. PLoS Med. 2020;17(9):e1003308. doi: 10.1371/journal.pmed.1003308

124. Kow CS, Hasan SS. The risk of mortality in patients with COVID19 with pre-diagnosis use of NSAIDs: A meta-analysis. Inflammopharmacology. 2021 Apr 21:1-4. doi: 10.1007/s10787-021-00810-1

125. South AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16(6):305-307. doi: 10.1038/s41581-020-0279-4

126. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Reninangiotensin-aldosterone system blockers and the risk of COVID19. N Engl J Med. 2020;382 25):2431-2440. doi: 10.1056/NEJMoa2006923

127. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med. 2020;382(25):2441-2448. doi: 10.1056/NEJMoa2008975

128. Egeli BH, Sparks JA, Kim AHJ, Liew JW. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? Best Pract Res Clin Rheumatol. 2021;35(1):101658. doi: 10.1016/j.berh.2020.101658

129. Ladapo JA, McKinnon JE, McCullough PA, Risch H. Randomized controlled trials of early ambulatory hydroxychloroquine in the prevention of COVID-19 infection, hospitalization, and death: meta-analysis. MedRxiv. 2020. doi: 10.1101/2020.09.30.20204693

130. Bansal P, Goyal A, Cusick A 4th, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021;53(1):117-134. doi: 10.1080/07853890.2020.1839959

131. Ferreira A, Oliveira ESA, Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2. J Med Virol. 2020;93(2):755-759. doi: 10.1002/jmv.26286

132. Gentry CA, Humphrey MB, Thind SK, Hendrickson SC, Kurdgelashvili G, Williams RJ 2nd. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: A retrospective cohort study. Lancet Rheumatol. 2020;2(11):e689-e697. doi: 10.1016/S2665-9913(20)30305-2

133. Rentsch CT, DeVito NJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, et al. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: A population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform. Lancet Rheumatol. 2021;3(1):e19-e27. doi: 10.1016/S2665-9913(20)30378-7

134. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-166. doi: 10.1038/s41584-020-0372-x

135. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819

136. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(9):1036-1041. doi: 10.1001/jamacardio.2020.1834

137. Favalli EG, Bugatti S, Klersy C, Biggioggero M, Rossi S, De Lucia O, et al. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther. 2020;22(1):290. doi: 10.1186/s13075-020-02395-6

138. Schäfer M, Strangfeld A, Hyrich KL, Carmona L, Gianfrancesco M, Lawson-Tovey S, et al. Response to: “Correspondence on “Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID19 Global Rheumatology Alliance physician reported registry’” by Mulhearn et al. Ann Rheum Dis. 2021 Mar 1. doi: 10.1136/annrheumdis-2021-220134

139. Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Pivonello R, et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020;43(8):1141-1147. doi: 10.1007/s40618-020-01266-w

140. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704. doi: 10.1056/NEJMoa2021436

141. Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, et al. Corticosteroids in COVID-19 and nonCOVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med. 2021;47(5):521-537. doi: 10.1007/s00134-021-06394-2

142. The REMAP-CAP Investigators, Gordon CA, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – Preliminary report. medRxiv 2021. doi: 10.1101/2021.01.07.21249390

143. RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G, Peto L, Brightling CE, Sarkar R, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): Preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021. doi: 10.1101/2021.02.11.21249258

144. Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020;131:110698. doi: 10.1016/j.biopha.2020.110698

145. Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: A meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021 May 21:1-12. doi: 10.1007/s00134-021-06416-z

146. Tardif J-C, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv. 2021. doi: 10.1101/2021.01.26.21250494

147. Алекберова ЗС, Насонов ЕЛ. Перспективы применения колхицина в медицине: новые данные. Научно-практическая ревматология. 2020;58(2):183-190. doi: 10.14412/1995-4484-2020-183-190

148. Chiu L, Chow R, Chiu N, Lo C-H, Aggarwal R, Lee J, et al. Colchicine use in patients with COVID-19: A systematic review and meta-analysis. medRxiv. 2021. doi: 10.1101/2021.02.02.21250960

149. Насонов ЕЛ, Лила АМ. Барицитиниб: новые возможности фармакотерапии ревматоидного артрита и других иммуновоспалительных ревматических заболеваний. Научнопрактическая ревматология. 2020;58(3):304-316. doi: 10.14412/1995-4484-2020-304-316

150. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020 Dec 11. doi: 10.1056/NEJMoa2031994

151. Mehta P, Ciurtin C, Scully M, Levi M, Chambers RC. JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. Eur Respir J. 2020;56(3):2001919. doi: 10.1183/13993003.01919-2020

152. Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2019:464.

153. Anderson RM, Vegvari C, Truscott J, Collyer BS. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. Lancet. 2020;396(10263):1614-1616. doi: 10.1016/S0140-6736(20)32318-7

154. Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11(10):754-765. doi: 10.1016/j.autrev.2012.02.001

155. Sarkar S, Khanna P, Singh AK. Impact of COVID-19 in patients with concurrent co-infections: A systematic review and meta-analyses. J Med Virol. 2021;93(4):2385-2395. doi: 10.1002/jmv.26740

156. Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on COVID-19 infection rates and severity. Am J Infect Control. 2021;49(6):694-700. doi: 10.1016/j.ajic.2021.02.012

157. Boekel L, Hooijberg F, van Kempen ZLE, Vogelzang EH, Tas SW, Killestein J, et al. Perspective of patients with autoimmune diseases on COVID-19 vaccination. Lancet Rheumatol. 2021;3(4):e241-e243. doi: 10.1016/S2665-9913(21)00037-0

158. Guidry JPD, Laestadius LI, Vraga EK, Miller CA, Perrin PB, Burton CW, et al. Willingness to get the COVID-19 vaccine with and without emergency use authorization. Am J Infect Control. 2021;49(2):137-142. doi: 10.1016/j.ajic.2020.11.018

159. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Gam-COVID-Vac Vaccine Trial Group. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3

160. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al.; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8

161. Schulze-Koops H, Specker C, Skapenko A. Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: Considerations before widespread availability of the vaccines. RMD Open. 2021;7(1):e001553. doi: 10.1136/rmdopen-2020-001553

162. Calabrese L, Winthrop KL. Rheumatology and COVID-19 at 1 year: Facing the unknowns. Ann Rheum Dis. 2021 March 3. doi: 10.1136/annrheumdis-2021-219957

163. Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: Evidence for impaired humoral but inducible cellular immune response. Ann Rheum Dis. 2021 May 6. doi: 10.1136/annrheumdis-2021-220408.

164. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. medRxiv. 2021 Apr 9. doi: 10.1101/2021.04.05.21254656

165. Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021 Mar 23. doi: 10.1136/annrheumdis-2021-220289

166. Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021 May 11. doi: 10.1136/annrheumdis-2021-220604

167. Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021 Mar 24. doi: 10.1136/annrheumdis-2021-220272

168. Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immunemediated inflammatory diseases. Ann Rheum Dis. 2021 May 6. doi: 10.1136/annrheumdis-2021-220461

169. Haberman RH, Herati R, Simon D, Samanovic M, Blank RB, Tuen M, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann Rheum Dis. 25 May 2021. doi: 10.1136/annrheumdis-2021-220597

170. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMoa2105385

171. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov19 vaccination. N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoa2104840

172. Goldman M, Hermans C. Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity. PLoS Med. 2021;18(5):e1003648. doi: 10.1371/journal.pmed.1003648.

173. Dotan A, Shoenfeld Y. Perspectives on vaccine induced thrombotic thrombocytopenia. J Autoimmun. 2021;121:102663. doi: 10.1016/j.jaut.2021.102663

174. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, et al.; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARSCoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1

175. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1

176. Белов БС. Вакцинация при ревматических заболеваниях: союзник или противник? Научно-практическая ревматология. 2018;56(4):401-404.

177. Westra J, Rondaan C, van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015;11(3):135-145. doi: 10.1038/nrrheum.2014.206

178. Furer V, Rondaan C, Heijstek MW, van Assen S, Bijl M, Breedveld FC, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882

179. Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveld FC, et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open. 2019;5(2):e001035. doi: 10.1136/rmdopen-2019-001035